宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02659 宝济药业-B

交易中 07-02 14:56:37

18.220

+0.220

+1.22%

最高19.210	最低17.870	成交量72.32万
今开18.000	昨收18.000	日振幅7.44%
总市值59.39亿	流通市值28.06亿	总股本3.26亿
成交额1,339万	换手率0.47%	流通股本1.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"宝济药业-B","latestPrice":18.22,"timestamp":1782975381006,"preClose":18,"halted":0,"volume":723197,"delay":0,"changeRate":0.012222222222222159,"floatShares":154000000,"shares":325981465,"eps":-1.571626910979159,"marketStatus":"交易中","change":0.22,"latestTime":"07-02 14:56:37","open":18,"high":19.21,"low":17.87,"amount":13390898,"amplitude":0.074444,"askPrice":18.35,"askSize":500,"bidPrice":18.22,"bidSize":700,"shortable":0,"etf":0,"ttmEps":-1.5519815745919192,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782979800000},"marketStatusCode":2,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":18,"openAndCloseTimeList":[[1782955800000,1782964800000],[1782968400000,1782979200000]],"volumeRatio":0.607988,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02659","defaultTab":"news","newsList":[{"id":"2647530875","title":"宝济药业-B(02659)6月30日斥资约168.63万港元回购9.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530875","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647530875?lang=zh_cn&edition=full","pubTime":"2026-06-30 18:52","pubTimestamp":1782816766,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B(02659)发布公告，于2026年6月30日该公司斥资约168.63万港元回购9.52万股，回购价格为每股17.38至17.81港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182826948","title":"宝济药业-B回购9.52万股股份，耗资约168.63万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182826948","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182826948?lang=zh_cn&edition=full","pubTime":"2026-06-30 18:52","pubTimestamp":1782816732,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年6月30日发布公告，披露当日在香港联合交易所回购公司H股股份。公告显示，此次回购数量合计95,200股，占此前公司已发行股本的约0.06169%。根据公告，本次回购价格区间为每股17.38港元至17.81港元，回购总金额为1,686,277.60港元。回购完成后，宝济药业-B已发行股本由154,327,250股减少至154,232,050股，另有95,200股被纳入库藏股，合计股本维持在154,327,250股。公告显示，宝济药业-B曾于2026年5月26日通过股份回购授权，最高可回购15,432,725股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B回购9.52万股股份，耗资约168.63万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156126212","title":"宝济药业-B宣布国家药监局批准BJ044注射液临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1156126212","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156126212?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:42","pubTimestamp":1782783720,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司（02659.HK）宣布，其BJ044注射液的临床试验申请已获得中国国家药品监督管理局的批准。此项批准意味着该药物将可进入临床研究阶段。\n公司进一步表示，此次获批是推进该候选药物研发进程中的关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647858680","title":"港股开盘偏软 恒指低开0.08% 携程集团-S(09961)跌2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647858680","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647858680?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:30","pubTimestamp":1782783038,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘偏软，科技股跑赢大盘，恒指低开0.08%，国企指数低开0.08%，恒生科技指数高开0.54%。现金要约价每股1.3875元，较6月29日收市价每股1.27元溢价约9.25%。港股昨日自低位回升，恒指高开后反复上扬，重上23,000点水平，整体成交保持活跃。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/ODE3MzYxNTg1NDgwMzI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODE3MzYxNTg1NDgwMzI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984796","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0231483743.USD","LU2476274308.USD","LU1993786604.SGD","LU0640798160.USD","BK1589","LU1831875114.USD","SG9999000475.SGD","LU2476274720.SGD","LU0231459107.USD","LU1048588211.SGD","HK0000306685.HKD","LU0823040885.USD","LU1868837722.USD","LU0856984785.SGD","LU1769817179.HKD","LU0211977185.USD","LU0819121731.USD","BK1604","BK1142","LU0541502299.USD","89888","LU0871576103.HKD","LU1102505762.USD","LU0328353924.USD","LU0797268264.HKD","LU0261950983.USD","BK1591","LU0132412106.USD","BK1504","LU0107464264.USD","LU0449509016.USD","LU0469268626.HKD","LU2039709279.SGD","LU1224709979.USD","LU0047713382.USD","BK1164","SG9999000327.SGD","LU1770036033.HKD","LU1064130708.USD","LU0384037296.USD","LU0918141705.HKD","BK1555","BK1095","LU0054237671.USD","LU0043850808.USD","LU0229945570.USD","LU1770034418.SGD","LU0540923850.HKD","LU0348825331.USD","LU0823397285.USD","LU1734074674.USD","LU0048580855.USD","BK1568","LU0819123356.HKD","BK1516","LU1188198961.HKD","SG9999001689.USD","LU0516423174.USD","SG9999002828.SGD","METmain","LU1323998911.USD","LU0307460666.USD","LU0589944569.HKD","LU1807302812.USD","HK0000288743.USD","LU1675838814.USD","LU0314109678.HKD","LU0143863198.USD","LU2097828631.EUR","LU0348814723.USD","BK1594","LU1720050803.USD","LU1794554557.SGD","02600","BK1258","LU1023057109.AUD","LU0633140560.USD","LU2449936058.SGD","IE0003851619.USD","LU0084288322.USD","LU0762541174.USD","BIDU","LU0455707207.USD","LU1961090484.USD","LU2097828805.USD","LU2087589342.USD","LU0049853897.USD","LU0039217434.USD","LU1917777945.USD","SG9999002463.SGD","BK1587","LU0737861699.HKD","LU0345780950.USD","LU2348773727.SGD","LU0061477393.USD","LU1956131251.USD","LU1504937902.USD","02899","BK1191","LU0269904917.USD","LU0345776255.USD","LU0140636845.USD","HK0001040143.USD","LU0823397103.USD","LU0588545730.USD","LU0630314457.HKD","LU0516422366.SGD","LU0117841782.USD","BK1601","LU0516422952.EUR","HK0000165453.HKD","LU0605514214.HKD","IE00B8L5B284.USD","BK1615","IE0008368742.USD","LU0348827113.USD","HK0000286598.CNH","LU2488822045.USD","LU1251922891.USD","LU0577902454.USD","LU0828237940.HKD","601899","LU0607220059.USD","LU0561508036.HKD","IE00B543WZ88.USD","BK1198","SG9999001903.USD","IE00B3M56506.USD","LU0266512473.USD","LU0672654166.SGD","LU0261950470.USD","LU0868486357.SGD","TCOM","IE00B5MMRT66.SGD","LU0541501648.USD","SG9999011746.SGD","IE0034224299.USD","LU0197773673.USD","LU0054450605.USD","LU0048575426.USD","LU1328615791.USD","01801","LU0348788117.USD","LU1303224171.USD","LU1282649067.USD","LU1481107354.HKD","LU1688375341.USD","LU0456827905.SGD","BK1592","HMTD.SI","LU0181495838.USD","02659","SG9999000459.SGD","LU2460026573.USD","LU0051755006.USD","LU1064131342.USD","LU0370786039.SGD","LU0128522157.USD","LU2125910500.SGD","LU0165289439.USD","BK1229","LU0531971595.HKD","LU0650527681.SGD","LU1880383366.USD","LU0067412154.USD","LU0214875030.USD","LU0164880469.USD","LU0499858438.USD","BK1513","BK1255","LU0821914370.USD","LU0823038988.USD","LU0417516571.SGD","LU0326950275.SGD","LU1808992512.USD","LU2177674079.SGD","IE00B031HY20.USD","LU0431992006.USD","LU0251144936.SGD","LU0593848301.USD","LU0456846285.SGD","LU0501845795.SGD","LU0634319403.HKD","LU0594300179.USD","LU0327786744.USD","IE0008369823.USD","LU0594300419.USD","BK1575","IE00B29SXG58.USD","LU0543330566.HKD","LU1008478684.HKD","09961","HK0001040168.HKD","LU0588545904.SGD","LU0683595622.HKD","LU1242518857.USD","IE00BF5LJ272.USD","LU1960683339.HKD","LU0700851271.USD","00780","LU1328277881.USD","LU0315178854.USD","LU0620787316.HKD","LU0164872284.USD","LU0210526637.USD","LU1969619763.USD","LU2045819591.USD","LU1988902786.USD","LU0873338254.USD","LU0143863784.USD","HK0000288784.HKD","LU1166156734.SGD","LU0588545490.SGD","LU0516423091.SGD","LU0611395673.USD","LU0828238088.HKD","LU0052750758.USD","NNFSF","01378","LU0244354667.USD","SGXZ90724238.SGD","LU0509642566.USD","LU1868837565.USD","LU0633140727.USD","LU0577902538.SGD","LU0287142896.SGD","HLPPY","LU2424517915.HKD","BK1608","LU2257852520.SGD","03692","LU1719994722.HKD","LU0577902298.EUR","LU2153591404.USD","LU0630378429.USD","LU2008162690.USD","LU0266512127.USD","LU0979878070.USD","LU0702159699.USD","LU0417516902.SGD","02559","BK1175","LU0572939691.SGD","LU1769817096.USD","LU1152091754.HKD","LU1813983027.USD","MPNGY","LU0326948709.USD","LU1282649810.SGD","LU0886674414.USD","LU2328871848.SGD","LU2399975544.HKD","LU2148510915.USD","LU2106854487.HKD","SG9999001051.SGD","LU1102505929.USD","LU0329678170.USD","09888","LU0880133367.SGD","LU0348735423.USD","LU0315179316.USD","LU0828237510.HKD","LU0823426480.USD","SG9999001226.SGD","LU0196878994.USD","LU3063872942.SGD","LU0348805143.USD","LU0543330483.HKD","03690","LU0029875118.USD","ZIJMY","LU0865486749.SGD","LU0329678337.USD","00027","BK1200","09633","LU0516422440.USD","LU0082770016.USD","LU0072462343.USD","LU0106959298.USD","LU0456854461.SGD","LU0149721374.USD","LU0572944931.SGD","LU2023250504.SGD","BK1172","LU1048596156.SGD","LU0320764755.SGD","LU0737861772.HKD","LU0359201612.USD","LU0164865239.USD","LU0572940350.SGD","LU2097828474.EUR","LU1282648689.USD","SG9999001093.SGD","HK0000306701.USD","LU0831093199.SGD","LU0588546209.SGD","BK1521","00101","LU1981816686.USD","LU2152927971.USD","LU0708995583.HKD","LU0577902611.USD","BK1618","LU0149534421.HKD","LU0823039010.USD","601600","LU0417516738.SGD","LU0918141887.USD","LU0823426308.USD","LU1242518931.SGD","LU0228659784.USD","LU0082770016.SGD","IE0032431581.USD","IE00BPRC5H50.USD","LU1974910355.USD","LU0488056044.USD","SG9999002562.SGD","BK1505","LU0630378692.HKD","LU1105468828.SGD","LU0096374516.USD","LU0345781412.USD","LU0348783233.USD","LU0502904849.HKD","BK1233","LU1880383440.USD","LU0463099449.HKD","LU0278937759.USD","HK0000320264.USD","BK1609","LU2264538146.SGD","SG9999014674.SGD","LU0359201885.HKD","LU1115378108.SGD","LU1868838027.USD","SG9999000418.SGD","LU0264606111.USD","LU0762542818.HKD","LU0048597586.USD","LU2097828557.USD","LU0345780521.USD","LU1211504680.USD","LU0072913022.USD","BK1544","LU0173614495.USD","LU0449515922.USD","IE00B0JY6N72.USD","LU0348784397.USD","BK1170","LU0823041008.USD","LU0348816934.USD","LU0320764599.SGD","LU0345780281.USD","LU0762540952.USD","BK1500","LU1152091168.USD","LU0345775950.USD","LU0577902371.SGD","LU2226246903.HKD","LU2778985437.USD","HK0000320223.HKD","LU0164939612.USD","LU0251143458.SGD","LU1064131003.USD","IE00B8HQ1Z84.USD","LU0359202008.SGD","LU0163747925.USD","BK1610","BK1583","IE0003795394.USD","LU0197773160.USD","LU2242644610.SGD","02382","LU0228367735.SGD","LU0878005551.USD","LU0106252389.USD","LU2097828714.EUR","SG9999004220.SGD","BK1588","LU0011963245.USD","BK1161","LU1226287529.USD","LU0499858602.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647585848","title":"港股公告掘金 | 医渡科技发布年度业绩 股东应占利润7270.9万元 成功实现从亏损到盈利的历史性跨越","url":"https://stock-news.laohu8.com/highlight/detail?id=2647585848","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647585848?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:07","pubTimestamp":1782781645,"startTime":"0","endTime":"0","summary":"重大事项：宝济药业-B(02659)：BJ044注射液(重组乌司他丁)临床试验申请获得国家药监局批准广和通(00638)拟14.28亿元收购航盛电子37.16%股权 实现“通信模组+汽车电子系统”的软硬件垂直整合晋景新能(01783)拟最高25亿港元收购YV CLOUD Limited及上海有孚云全部股权 布局 IDC 及 AI 算力业务佑驾创新(02431)：全场景物理AI合资公司完成注册设立I","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1189","BK4588","BK1214","02158","BK1161","BK1617","BK1148","02659","BK1518","BK4585","00638","01783","VXUS","02431","BK1144","BK1149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647347425","title":"港股异动 | 宝济药业-B(02659)早盘涨超10% KJ103新药上市许可申请近期获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2647347425","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647347425?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:06","pubTimestamp":1782702414,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B早盘涨超10%，截至发稿，涨9.01%，报17.9港元，成交额1951.63万港元消息面上，宝济药业此前宣布，其自主研发的注射用KJ103新药上市许可申请获国家药品监督管理局受理，并将其已纳入优先审评程序，拟用于高度致敏的肾移植患者的脱敏治疗。据悉，宝济药业首款产品长效促卵泡素SJ02于2025年8月获批上市，11月完成首批订单交付，标志公司正式进入商业化阶段；核心产品重组人透明质酸酶KJ017已于2026年3月31日获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IPOS","02659","BK1161","BK4588","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442824","title":"宝济药业-B：皮下输注用头孢曲松钠BJ007临床试验获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442824","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642442824?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:05","pubTimestamp":1781089500,"startTime":"0","endTime":"0","summary":"6月10日，宝济药业-B（02659）发布公告，公司于2026年5月27日获得美国食品药品监督管理局(FDA)批准，开展皮下输注用头孢曲松钠BJ007的临床试验。BJ007是用于治疗细菌感染的皮下给药头孢曲松钠产品，全球尚无皮下给药头孢曲松钠获得批准，BJ007为该类别首款进入临床阶段的候选药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606103766846240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LABU","BK1161","BK4585","BK4588","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193162360","title":"美国FDA于2026年5月27日批准宝济药业-B注射用Bj007皮下输注的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1193162360","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193162360?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:28","pubTimestamp":1781087298,"startTime":"0","endTime":"0","summary":"宝济药业-B宣布，其研发的注射用Bj007于2026年5月27日获得美国食品药品监督管理局（FDA）批准，可开展皮下输注给药途径的新药临床试验。这一监管进展标志着该药物在探索新的给药方式上迈出了关键一步，为其后续的临床开发路径奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134258497","title":"异动解读｜宝济药业-B盘中下跌5.19%，闪崩后低位震荡延续叠加生物科技板块部分个股承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1134258497","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134258497?lang=zh_cn&edition=full","pubTime":"2026-06-08 11:54","pubTimestamp":1780890840,"startTime":"0","endTime":"0","summary":"6月8日，宝济药业-B盘中下跌5.19%，报20.48港元/股，成交额1635.37万港元。消息面上，公司股价自4月底闪崩暴跌65%后持续低位震荡，尽管近期已落定新董事长、获纳入MSCI全球指数、核心管线KJ103上市申请获国家药监局受理等多重利好催化，但市场信心仍处修复阶段。生物科技板块今日部分个股承压，其中信达生物跌3.59%、三生制药跌2.3%、康方生物跌0.27%，行业情绪偏弱加剧个股回调压力。当前股价已跌破此前52周新低，成交额较前期明显萎缩，显示市场观望情绪浓厚。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195643371","title":"异动解读｜宝济药业-B盘中上涨5.59%，核心管线KJ103上市申请获受理叠加生物科技板块回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=1195643371","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195643371?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:41","pubTimestamp":1780623718,"startTime":"0","endTime":"0","summary":"6月5日，宝济药业-B盘中上涨5.59%，报23.94港元/股，成交额1727.3万港元。消息面上，公司6月4日公告自主研发的注射用KJ103新药上市许可申请获国家药品监督管理局受理，用于高度致敏肾移植患者脱敏治疗，并已于5月20日获纳入优先审评程序。KJ103为全球首创低免疫原性IgG降解酶，III期临床数据显示移植前脱敏成功率及肾脏移植成功率均达100%。此外，生物科技板块今日整体回暖，科伦博泰生物涨6.87%、信达生物涨2.94%、康方生物涨1.76%，行业情绪修复提振个股表现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640815529","title":"宝济药业-B(02659)：注射用KJ103上市许可申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640815529","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640815529?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:29","pubTimestamp":1780565343,"startTime":"0","endTime":"0","summary":"于2024年11月19日该适应症被NMPA药品审评中心批准纳入突破性治疗认定。KJ103目前已完成III期临床试验所有入组受试者的主要试验随访，已完成的临床试验可支持该产品的上市许可申请。KJ103给药后可迅速有效地降低或消除HLA 抗体，于移植前实现100%的脱敏治疗成功率和100%的肾脏移植成功率，3个月以上移植物存活率为100%。此外，本公司也在积极探索KJ103在其他抗体介导的急性自身免疫性疾病的治疗潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IPOS","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163397983","title":"异动解读｜宝济药业-B盘中上涨13.37%，超跌反弹叠加多重利好催化修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1163397983","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163397983?lang=zh_cn&edition=full","pubTime":"2026-06-04 13:12","pubTimestamp":1780549929,"startTime":"0","endTime":"0","summary":"6月4日，宝济药业-B盘中上涨13.37%，报23.98港元/股，成交额3794.29万港元。消息面上，公司此前连续两个交易日跟随生物科技板块系统性走弱分别下跌5.46%及5.3%，股价触及52周新低22.90港元后出现强势反弹。此外，公司已被纳入MSCI全球指数，前期被动资金调仓抛压消化后，市场信心进入修复阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122877857","title":"异动解读｜宝济药业-B盘中下跌5.3%，生物科技板块系统性走弱延续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1122877857","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122877857?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:52","pubTimestamp":1780386730,"startTime":"0","endTime":"0","summary":"6月2日，宝济药业-B盘中下跌5.3%，报21.82港元/股，成交额3912.25万港元。消息面上，生物科技板块今日延续系统性走弱态势，行业个股普遍承压，其中三生制药跌8.8%、康方生物跌8.28%、科伦博泰生物跌7.35%、信达生物跌2.6%、百济神州跌1.52%，板块整体抛压显著。公司股价自4月底闪崩暴跌65%后持续低位震荡，尽管近期新董事长刘彦君落定、中邮证券首予\"增持\"评级、获纳入MSCI全球指数等多重利好催化，但市场信心仍处于修复阶段，在行业系统性回调背景下个股跟随走弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127894406","title":"宝济药业-B公布2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1127894406","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127894406?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:08","pubTimestamp":1780304924,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年6月1日发布2026年5月的证券变动月报表。报告显示，截至5月31日，公司各类已发行股份总体数量保持不变，未进行任何新增发行、购回或注销行为，股本结构稳定。公司本月底法定/注册股本总额为65,196,293元人民币。公告由公司执行董事刘彦君签署，并重申公司遵守香港联交所《上市规则》及其他相关法律规定。根据公告信息显示，公司目前股本维持不变，符合相关监管要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117543784","title":"异动解读｜宝济药业-B盘中下跌5.46%，MSCI纳入生效首日遭抛压叠加板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1117543784","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117543784?lang=zh_cn&edition=full","pubTime":"2026-06-01 14:36","pubTimestamp":1780295769,"startTime":"0","endTime":"0","summary":"6月1日，宝济药业-B盘中下跌5.46%，报23.2港元/股，成交额4265.7万港元。消息面上，公司此前获纳入MSCI全球指数成分股，于5月29日收市后正式生效，今日为生效后首个交易日。此外，生物科技板块今日整体承压，百济神州跌3.45%、科伦博泰生物跌6.8%、信达生物跌2.88%，行业系统性走弱加剧个股回调。公司股价自4月底闪崩暴跌65%后持续低位震荡，尽管近期新董事长落定、中邮证券首予\"增持\"评级，但市场信心仍处于修复阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640933019","title":"【券商聚焦】中邮证券首予宝济药业-B(02659)“增持”评级 指公司商业化元年开启","url":"https://stock-news.laohu8.com/highlight/detail?id=2640933019","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640933019?lang=zh_cn&edition=full","pubTime":"2026-06-01 13:55","pubTimestamp":1780293315,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中邮证券发布研报指，2025年宝济药业-B 实现总收入4916万元，较2024年的616万元大幅增长，主要得益于4000万元许可收入及首款商业化产品SJ02（晟诺娃）的364万元净收入。年内亏损3.95亿元，亏损同比扩大主要受计提5510万元诉讼拨备等非经营性因素影响。业务层面，首款产品长效促卵泡素SJ02于2025年8月获批上市，11月完成首批订单交付，标志公司进入商业化阶段。核心产品重组人透明质酸酶KJ017于2026年3月31日获批，系国内首款获批产品。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639642125","title":"中邮证券：首予宝济药业-B(02659)“增持”评级 平台价值逐步兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2639642125","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639642125?lang=zh_cn&edition=full","pubTime":"2026-05-29 14:07","pubTimestamp":1780034864,"startTime":"0","endTime":"0","summary":"公司首款产品长效促卵泡素SJ02于2025年8月获批上市，11月完成首批订单交付，标志公司正式进入商业化阶段。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260529/20260529140811_37744.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260529/20260529140811_37744.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02659","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129712989","title":"异动解读｜宝济药业-B盘中上涨5.05%，新任董事长落定叠加管线利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1129712989","media":"行情直击","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129712989?lang=zh_cn&edition=full","pubTime":"2026-05-27 14:50","pubTimestamp":1779864600,"startTime":"0","endTime":"0","summary":"5月27日，宝济药业-B盘中上涨5.05%，报26.24港元/股，成交额8176.22万港元。消息面上，公司于5月26日公告，刘彦君博士获委任为第二届董事会董事长，任期三年。此外，近期公司核心管线注射用KJ103拟纳入优先审评，该产品为全球首创的重组IgG降解酶，适用于高度致敏肾移植患者脱敏治疗。此前公司股价自4月底闪崩暴跌65%后持续低位运行，控股股东已表态拟增持股份，新管理层架构确立叠加研发管线推进，市场情绪有所修复。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638510008","title":"宝济药业-B(02659)：刘彦君获委任为董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2638510008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638510008?lang=zh_cn&edition=full","pubTime":"2026-05-26 21:58","pubTimestamp":1779803887,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，刘彦君博士、王征女士及李翠女士获重选为第二届董事会执行董事;林佳陵女士、刁隽桓先生及LiChen先生获重选为第二届董事会非执行董事;及蔡仲曦先生、曾凡一博士、鞠佃文博士及张森泉先生获重选为第二届董事会独立非执行董事。于紧随股东周年大会后举行的第二届董事会第一次会议上，刘彦君博士获委任为第二届董事会董事长，任期自2026年5月26日起至第二届董事会任期届满之日止为期三年。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111545287","title":"异动解读｜宝济药业-B盘中下跌5.02%，报25.36港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111545287","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111545287?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:35","pubTimestamp":1779330952,"startTime":"0","endTime":"0","summary":"5月21日，宝济药业-B盘中下跌5.02%，报25.36港元/股，成交额3535.91万港元。宝济药业-B所在的生物科技行业中，板块整体表现偏强，个股中，康方生物涨5.91%，荣昌生物涨4.31%，信达生物涨2.96%，百济神州涨1.93%，三生制药涨0.36%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baopharma.com","stockEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":-0.2665},{"period":"3month","weight":-0.8154},{"period":"6month","weight":-0.7679},{"period":"1year","weight":-0.3177},{"period":"ytd","weight":-0.7679}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1073},{"period":"1year","weight":-0.0495},{"period":"ytd","weight":-0.1073}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海宝济药业股份有限公司专注于重组蛋白药物和抗体药物的产业化与商业化。我们在上海建设了符合cGMP标准的生产基地，占地约63,000平方米，规划了多条覆盖哺乳动物细胞表达系统及大肠杆菌/酵母表达系统的原液生产线，以及水针剂、冻干粉针剂和一次性预灌封制剂的成品生产线。","exchange":"SEHK","name":"宝济药业-B","nameEN":"BAO PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宝济药业-B,02659,宝济药业-B股票,宝济药业-B股票老虎,宝济药业-B股票老虎国际,宝济药业-B行情,宝济药业-B股票行情,宝济药业-B股价,宝济药业-B股市,宝济药业-B股票价格,宝济药业-B股票交易,宝济药业-B股票购买,宝济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}